PuSH - Publikationsserver des Helmholtz Zentrums München

Zissler, U.M. ; Jakwerth, C.A. ; Guerth, F. ; Pechtold, L. ; Aguilar-Pimentel, J.A. ; Dietz, K. ; Suttner, K. ; Piontek, G.* ; Haller, B.* ; Hajdu, Z.* ; Schiemann, M.* ; Schmidt-Weber, C.B. ; Chaker, A.

Early IL-10 producing B-cells and coinciding Th/Tr17 shifts during three year grass-pollen AIT.

EBioMedicine 36, 475-488 (2018)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Background: Allergen specific immunotherapy (AIT) is a causative treatment in allergic airway disease, comprising long-term allergen administration and requiring three years of treatment. Mechanisms and biomarkers that translate into clinical efficacy remain urgently needed.Methods: In an exploratory observational allergy cohort we phenotyped 32 grass-pollen allergic patients with hayfever undergoing AIT for over three years and controls using local and systemic samples for ex vivo FACS, nasal transcriptomes and in vitro phleum-stimulation at critical time windows six hours after therapeutic allergen administration and during peak-season responses.Findings: The up-dosing phase is marked by increased IL-10(+) B-cells with allergen-specific PD-L1 up-regulation. while effector Th1/Th17 cells and CCR6(+)IL-17(+)FoxP3(+) T-cells decrease. The conversion phase exhibits Th17 recovery in the absence of Th2 cells. The tolerance-mounting phase after three years of treatment is characterized by induction of Tregs while Th2 and phleum-specific Th17 responses decrease. Notably, high ratios of circulating Breg/Th17 following initial AIT correlate significantly with clinical improvement after three years.Interpretation: Our exploratory data hypothezise differential shifts in the hierarchy of tolerance in three distinct phases of AIT characterized by conversion of regulatory against pro-inflammatory mechanisms, of which the Breg/Th17 ratio after initial treatment emerges as potential early prediction of AIT efficacy. (C) 2018 The Authors. Published by Elsevier B.V.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Allergic Rhinitis ; Allergy ; Specific Immunot Herapy ; Biomarker ; Prediction ; Surrogate ; Tolerance ; Regulatory Bells (bregs) ; Regulatory T-cells (tregs); Regulatory T-cells; Allergen Immunotherapy; Clinical-efficacy; Mast-cells; Hay-fever; Responses; Expression; Induction; Immunity; Mucosal
ISSN (print) / ISBN 2352-3964
e-ISSN 2352-3964
Zeitschrift EBioMedicine
Quellenangaben Band: 36, Heft: , Seiten: 475-488 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam [u.a.]
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Allergy Research (IAF)